Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 3/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411636 | 1.00 | NOD1 (0.53) | NOD1GNAI3GNAO1GNAI1TLR2 | |
| SCHEMBL444217 | 1.00 | NOD1 (0.53) | NOD1GNAI3GNAO1GNAI1TLR2 | |
| SCHEMBL444219 | 1.00 | NOD1 (0.53) | NOD1GNAI3GNAO1GNAI1TLR2 | |
| SCHEMBL444218 | 1.00 | NOD1 (0.53) | NOD1GNAI3GNAO1GNAI1TLR2 | |
| SCHEMBL8520845 | 0.96 | NOD1 (0.54) | NOD1GNAI3GNAO1GNAI1TLR2 | |
| SCHEMBL13562003 | 0.94 | SLC6A5 (0.49) | NOD1GNAI3GNAO1GNAI1TLR2 | |
| Hydrochloric Acid SCHEMBL31420399 | 0.93 | SLC6A5 (0.48) | NOD1GNAI3GNAO1GNAI1TLR2 | |
| SCHEMBL27779757 | 0.92 | NOD1 (0.61) | NOD1GNAI3GNAO1GNAI1TLR2 | |
| SCHEMBL905947 | 0.89 | GNAI3 (0.52) | NOD1GNAI3GNAO1GNAI1TLR2 | |
| SCHEMBL13050781 | 0.89 | GNAI3 (0.52) | NOD1GNAI3GNAO1GNAI1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080131455-A1 | Antigen Delivery Compositions And Methods Of Use | PDS BIOTECHNOLOGY CORPORATION (US) | 2008-06-05 | — | — | US | claimed |
| US-7303881-B2 | Antigen delivery compositions and methods of use | PDS BIOTECHNOLOGY CORPORATION (US) | 2007-12-04 | — | — | US | claimed |
| WO-2025235559-A1 | IL-12 FUSION PROTEIN FORMULATIONS AND METHODS OF USE THEREOF | PDS BIOTECHNOLOGY CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2024086169-A2 | NOVEL NON-HLA RESTRICTED T CELL VACCINE FOR TCR GAMMA ALTERNATE READING FRAME PROTEIN (TARP) PROTEIN EXPRESSING CANCERS | PDS BIOTECHNOLOGY CORPORATION (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024086380-A2 | RECOMBINANT PROTEIN VACCINES FORMULATED WITH ENANTIO-SPECIFIC CATIONIC LIPID R-DOTAP AND METHODS OF USE THEREOF | PDS BIOTECHNOLOGY CORPORATION (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024086290-A2 | NOVEL T CELL ACTIVATING IMMUNOTHERAPEUTIC FOR TREATMENT OF MUCIN 1 PROTEIN EXPRESSING HUMAN CANCERS | PDS BIOTECHNOLOGY CORPORATION (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11911359-B2 | Stimulation of an immune response by cationic lipids | PDS BIOTECHNOLOGY CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-11904015-B2 | Vaccine compositions and methods of use | PDS BIOTECHNOLOGY CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-11801257-B2 | Stimulation of an immune response by enantiomers of cationic lipids | PDS BIOTECHNOLOGY CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
| EP-4247493-A1 | METHODS AND COMPOSITIONS COMPRISING CATIONIC LIPIDS FOR IMMUNOTHERAPY BY DIRECT TUMOR INJECTION | PDS Biotechnology Corporation (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230285551-A1 | LIPIDS AS SYNTHETIC VECTORS TO ENHANCE ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY | PDS BIOTECHNOLOGY CORPORATION | 2023-09-14 | — | — | US | disclosed |
| EP-2276495-A1 | STIMULATION OF AN IMMUNE RESPONSE BY ENANTIOMERS OF CATIONIC LIPIDS | PDS Biotechnology Corporation (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2125011-A2 | STIMULATION OF AN IMMUNE RESPONSE BY CATIONIC LIPIDS | PDS Biotechnology Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009129227-A1 | STIMULATION OF AN IMMUNE RESPONSE BY ENANTIOMERS OF CATIONIC LIPIDS | PDS BIOTECHNOLOGY CORPORATION (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090017057-A1 | STIMULATION OF AN IMMUNE RESPONSE BY CATIONIC LIPIDS | PDS BIOTECHNOLOGY CORPORATION (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2008116078-A9 | STIMULATION OF AN IMMUNE RESPONSE BY CATIONIC LIPIDS | PDS BIOTECHNOLOGY CORP (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008116078-A2 | STIMULATION OF AN IMMUNE RESPONSE BY CATIONIC LIPIDS | PDS BIOTECHNOLOGY CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080131455-A1 | Antigen Delivery Compositions And Methods Of Use | PDS BIOTECHNOLOGY CORPORATION (US) | 2008-06-05 | — | — | US | disclosed |
| US-7303881-B2 | Antigen delivery compositions and methods of use | PDS BIOTECHNOLOGY CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060008472-A1 | Antigen delivery compositions and methods of use | PDS BIOTECHNOLOGY CORPORATION | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11801257-B2 | Stimulation of an immune response by enantiomers of cationic lipids | C3AR1, FFAR1, FFAR3 | NOD1 449/4885GNAI3 1372/4885GNAO1 2951/4885 |
| US-20080131455-A1 | Antigen Delivery Compositions And Methods Of Use | CD74, CD47, HAVCR2 | NOD1 552/4885GNAI3 1705/4885GNAO1 4070/4885 |
| US-20090017057-A1 | STIMULATION OF AN IMMUNE RESPONSE BY CATIONIC LIPIDS | CD69, CD14, MYD88 | NOD1 408/4885GNAI3 598/4885GNAO1 3084/4885 |
| US-11911359-B2 | Stimulation of an immune response by cationic lipids | CD69, CD14, MYD88 | NOD1 408/4885GNAI3 598/4885GNAO1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.